Henry Tran, MD
Cardiovascular Disease · Falls Church, VANPI 1689895153
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,200 of the $3,909 with a category attached, or 81.9%. 28 manufacturers reported payments, led by Novartis at 35.1% of the total. 2025 is the largest year on record at $1,489, 7.0 times the $213 reported in 2019.
Across 85 payments — averaging $45.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- E.r. Squibb & Sons, L.L.C.$592
- Abbott$462
- Amgen$284
- Lilly USA, LLC$142
- Medtronic$140
- plus $915 from 22 others
Across 511 payments — averaging $3163.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$488K
- Novo Nordisk AS$453K
- Ortho-clinical Diagnostics, Inc.$447K
- Amgen$90K
- Bayer$57K
- Siemens Medical Solutions USA, Inc.$39K
- plus $43K from 3 others
What the payments were for
- Travel & lodging$70918%
- Food & beverage$3,20082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $1,373 |
| E.r. Squibb & Sons, L.L.C. | 12 | $592 |
| Abbott | 3 | $462 |
| Amgen | 9 | $284 |
| Lilly USA, LLC | 7 | $142 |
| Medtronic(2 entities) | 4 | $140 |
| Novo Nordisk | 1 | $115 |
| Johnson & Johnson | 4 | $92 |
| AbbVie | 3 | $84 |
| Eisai Inc. | 3 | $65 |
| Bardy Diagnostics, Inc. | 3 | $62 |
| Alnylam Pharmaceuticals Inc. | 1 | $57 |
| Boston Scientific | 2 | $48 |
| UCB, Inc. | 2 | $43 |
| Boehringer Ingelheim | 2 | $41 |
| Pfizer | 2 | $37 |
| Genentech USA, Inc. | 2 | $37 |
| Philips North America LLC | 1 | $30 |
| Cvrx, Inc. | 1 | $27 |
| Amneal Pharmaceuticals LLC | 1 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Acorda Therapeutics, Inc | 1 | $22 |
| Neurelis, Inc. | 1 | $20 |
| Corium, LLC | 2 | $20 |
| Biogen | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| CSL Behring | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,909 in reported general payments places this provider in the 70th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Falls Church
- Alexander TruesdellFalls Church$167K
- Christopher OconnorFalls Church$161K
- Joseph KreppFalls Church$74K
- Behnam TehraniFalls Church$58K
- Mitchell PsotkaFalls Church$35K
- Tariq HaddadFalls Church$18K
- Leonard IlkhanoffFalls Church$14K
- Shashank SinhaFalls Church$12K
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.